{
  "id": "5c61bd04e842deac67000002",
  "type": "list",
  "question": "Which two drugs are included in the Entresto pill?",
  "ideal_answer": "Entresto includes Sacubitril and Valsartan.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30084228",
    "http://www.ncbi.nlm.nih.gov/pubmed/27697814",
    "http://www.ncbi.nlm.nih.gov/pubmed/28944989",
    "http://www.ncbi.nlm.nih.gov/pubmed/28676030",
    "http://www.ncbi.nlm.nih.gov/pubmed/26976916",
    "http://www.ncbi.nlm.nih.gov/pubmed/27284124",
    "http://www.ncbi.nlm.nih.gov/pubmed/26975167",
    "http://www.ncbi.nlm.nih.gov/pubmed/27804100",
    "http://www.ncbi.nlm.nih.gov/pubmed/29375230",
    "http://www.ncbi.nlm.nih.gov/pubmed/30276760",
    "http://www.ncbi.nlm.nih.gov/pubmed/29469206",
    "http://www.ncbi.nlm.nih.gov/pubmed/26417173",
    "http://www.ncbi.nlm.nih.gov/pubmed/29352367",
    "http://www.ncbi.nlm.nih.gov/pubmed/28824789",
    "http://www.ncbi.nlm.nih.gov/pubmed/26466333",
    "http://www.ncbi.nlm.nih.gov/pubmed/28883863",
    "http://www.ncbi.nlm.nih.gov/pubmed/29398176",
    "http://www.ncbi.nlm.nih.gov/pubmed/29532764"
  ],
  "snippets": [
    {
      "text": "A novel antihypertensive drug, LCZ696 (Entresto\u00ae), has recently been introduced, which combines the action of an antagonist of the renin-angiotensin-aldosterone system (RAAS), effectively decreasing the blood pressure, with an inhibition of neprilysin, which is responsible for metabolizing natriuretic peptides exerting antihypertensive and antifibrotic effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28944989",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS AND RESULTS: The ENTRESTO-SAS trial is a 3-month, multicentric, prospective, open-label real-life cohort study. Patients eligible for sacubitril-valsartan treatment (i.e. adults with left ventricular ejection fraction \u226435%, who remain symptomatic despite optimal treatment with an angiotensin-converting enzyme inhibitor, a beta-blocker, and a mineralocorticoid receptor antagonist) will be evaluated before and after 3\u00a0months of treatment (nocturnal ventilatory polygraphy, echocardiography, laboratory testing, and quality-of-life and SDB questionnaires). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29469206",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " We sought to assess in the ENTRESTO-SAS trial whether sacubitril-valsartan could improve the outcome of SDB in CHF patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29469206",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This positive change in regulatory perspective coupled with successful commercialization of valsartan-sacubitril co-crystal (Entresto, Novartis) has now brought co-crystals into focus, in both industries as well as academia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29352367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present a case of a 61-year-old man with ischemic cardiomyopathy receiving sacubitril/valsartan (Entresto; Novartis, Cambridge, MA) who developed profound hypotension after HT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29398176",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor for the use in Heart Failure with Reduced Ejection Fraction (HFrEF) patients instead of ACEI's and ARBs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29532764",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30084228",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This review of the literature highlights the new generation of HF drug, sacubitril-valsartan (SV), trade name Entresto (researched as LCZ696, Novartis) which simultaneously blocks RAAS and NP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28824789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u25bc Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26417173",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?The original version of this article unfortunately contained a mistake. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30276760",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Sacubitril, Valsartan"
}